M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.82 EUR 2.09% Market Closed
Market Cap: 108.6m EUR
Have any thoughts about
Maat Pharma SA?
Write Note

EV/EBIT
Enterprise Value to EBIT

-3.5
Current
-4.5
Median
4.1
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-3.5
=
Enterprise Value
84.6m EUR
/
EBIT
-24.2m EUR
All Countries
Close
Market Cap EV/EBIT
FR
Maat Pharma SA
PAR:MAAT
108.8m EUR -3.5
FR
Pharnext SCA
OTC:PNEXF
6T USD -215 658.5
US
Abbvie Inc
NYSE:ABBV
320.1B USD 24.1
US
Amgen Inc
NASDAQ:AMGN
150.5B USD 31.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD 26.3
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD 10
US
Epizyme Inc
F:EPE
94.1B EUR -504.1
AU
CSL Ltd
ASX:CSL
135.4B AUD 25.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.9B USD 18.1
US
Seagen Inc
F:SGT
39.3B EUR -53.4
NL
argenx SE
XBRU:ARGX
34.5B EUR -76.6
EBIT Growth
FR
M
Maat Pharma SA
PAR:MAAT
Average EV/EBIT: 22.6
Negative Multiple: -3.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 658.5 N/A
US
Abbvie Inc
NYSE:ABBV
24.1
88%
US
Amgen Inc
NASDAQ:AMGN
31.8
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -504.1 N/A
AU
CSL Ltd
ASX:CSL
25.5
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.1
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.6 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-3
2-Years Forward
EV/EBIT
-3.7
3-Years Forward
EV/EBIT
-21.6

See Also

Discover More